Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Intra-cellular Therapies Inc. is managing 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 9 distinct examiners, meaning every pending matter is handled by a different individual. This distribution of examiners shows a variety of perspectives across the company's active applications.
The 9 pending actions are situated within 6 distinct art units. This indicates that while the examiners are unique for every action, some art units are handling more than 1 application for the company. The count of 6 art units compared to 9 examiners shows that the technical focus is more consolidated than the individual examiner assignments. Practitioners must navigate the specific nuances of 6 different art unit environments.
KIFLE, BRUCK is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Given that there are 9 distinct examiners for 9 actions, no individual examiner holds more than 1 pending action. This lack of examiner concentration means the company must tailor its prosecution strategies to 9 different sets of examiner preferences within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| Double-patenting only | 2 (22%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18042103 | ORGANIC COMPOUNDS | FETTEROLF, BRANDON J | 3d overdue |
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
| 18847121 | ORGANIC COMPOUNDS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18741740 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | O DELL, DAVID K | — |
| 18481168 | NOVEL METHODS | RODRIGUEZ-GARCIA, VALERIE | — |
| 18320173 | NOVEL METHODS | CHONG, YONG SOO | — |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1600 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18847121 | ORGANIC COMPOUNDS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18777765 | NOVEL METHODS | SHIAO, REI TSANG | — | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18741740 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | O DELL, DAVID K | 1621 | §102§103DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18481168 | NOVEL METHODS | RODRIGUEZ-GARCIA, VALERIE | 1600 | §103DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18320173 | NOVEL METHODS | CHONG, YONG SOO | 1623 | DP | Final Rejection | — | Pending | May 18, 2023 |
| 18042103 | ORGANIC COMPOUNDS | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 17, 2023 |
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Non-Final OA | 60d overdue | Pending | Jan 26, 2023 |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial